Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.
Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.
Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.
Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.
Quest Diagnostics (DGX) has raised its financial outlook for full year 2020, anticipating net revenues of at least $9.35 billion, up from a previous estimate of $8.8 billion. The company expects a 21.0% revenue increase and reported diluted EPS of at least $9.98. Despite a decline in organic testing volumes in December, COVID-19 molecular testing volumes have exceeded prior expectations. The revised outlook includes cash from operations of at least $1.95 billion and capital expenditures around $420 million.
Quest Diagnostics (NYSE: DGX) announced collaborations with Montefiore Nyack Hospital and Goshen Hospital to enhance diagnostic services. The relationships will include management of hospital laboratories, supply chain management, and esoteric reference testing. Steve Rusckowski, CEO, highlighted the increasing demand from health systems for Quest's laboratory strategy support. As Quest serves a significant portion of the U.S. population, these partnerships aim to improve healthcare management and patient outcomes while addressing the challenges faced by hospitals.
Quest Diagnostics (DGX) declared a quarterly cash dividend of $0.56 per share, payable on February 3, 2021. Shareholders must be on record by January 20, 2021 to receive the dividend. The company aims to empower health improvements, servicing a significant portion of adult Americans and healthcare providers in the United States. Quest Diagnostics continues to utilize its diagnostic insights for better health outcomes.
Quest Diagnostics (NYSE: DGX) announced its participation in the Credit Suisse 29th Annual Virtual Healthcare Conference. CEO Steve Rusckowski will present on the company's vision, growth strategy, and operational excellence, focusing on the COVID-19 pandemic's impact. The event will take place on November 10, 2020, at 11:45 a.m. ET. The presentation will be webcast live and available afterward on the company's investor relations page until December 10, 2020. Quest Diagnostics continues to lead in COVID-19 testing and diagnostics, providing essential healthcare services.
Quest Diagnostics (DGX) reported strong Q3 2020 results, with net revenues of $2.786 billion, a 42.5% increase from the previous year. The company attributed growth to heightened demand for COVID-19 testing and a recovery in healthcare utilization. Operating income reached $718 million, up 129.5%. Diluted EPS soared to $4.14, marking a 164.6% increase. Quest raised its full-year revenue outlook to a range of $8.8 to $9.1 billion, reflecting confidence in ongoing demand and operational recovery.
Quest Diagnostics released a Health Trends study revealing a significant rise in misuse of fentanyl, heroin, and nonprescribed opioids, attributed to the COVID-19 pandemic's impact on healthcare access. Analysis of over 872,000 lab results showed a 35% increase in fentanyl positivity and 44% for heroin during the pandemic. Notably, drug mixing incidents surged significantly, presenting greater risks. The study highlights men as the most affected demographic, with a 51% increase in illicit fentanyl use. However, gabapentin misuse saw a 21% decline.
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
